• Biotechnology
  • Friday, 06 Sep 2019

Drug abuse testing to grow at a fastest rate, due to cost-effective, easy, and quick method

Publisher: The Insight Partners

According to a new market research study titled ‘Drug Abuse Testing Market to 2027 – Global Analysis and Forecasts by Product, Sample Type and End User.’ The global drug abuse testing market is expected to reach US$ 9,393.17 Mn in 2027 from US$ 5,783.71 Mn in 2018. The market is estimated to grow with a CAGR of 5.7% from 2019-2027. The report highlights the trends prevalent in the global drug abuse testing market and the factors driving the market along with those that act as deterrents to its growth.

Drug abuse testing is used to perform to detect and evaluate overdose and drug intoxication. Cocaine, Marijuana, Opiates, LSD, Cannabinoids, Amphetamines, Alcohol, Diazepam, and Ketamine, are commonly used drugs of abuse. The type of drug tests varies and depending on the type of drug being tested and the type of specimen being collected. The test specimens include such as hair, urine, saliva (oral fluid) for the testing.

Global drug abuse testing market, based on sample type, was segmented as, urine, saliva, blood and others. In 2018, urine segment led the market by the sample type. In addition, the segment is also expected to grow at a fastest rate, due to cost-effective, easy, and quick method

The major players operating in the drug abuse testing market are, Redwood Toxicology Laboratory (Abbott), F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., OraSure Technologies, Inc., UCP Biosciences, MEDACX Ltd., Beckman Coulter, Inc. (Danaher), Alcolizer Pty Ltd., Wondfo, DRÄGERWERK AG & CO. KGAA, American Screening Corporation, Inc, Mercedes Medical, Alfa Scientific Designs, Inc., Express Diagnostics Int'l, Inc., Omega Laboratories, Inc. and Laboratorio Sodré. Organic activities such as product launch, expansion, and product development have been undertaken by the players in the market in order to improve their position in the drug abuse testing market. For instance, in April, 2019, Thermo Fisher Scientific, announced availability of Thermo Scientific CEDIA Mitragynine Assay, it is the newest drugs of abuse test which includes supporting calibrators and controls.


Related News